Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Egeberg, Alexander; Bo Ottosen, Mathias; Gniadecki, Robert; Broesby‐Olsen, Sigurd; Dam, T.N.; Erik Bryld, Lars; Kirchheiner Rasmussen, Mads; Skov, Lone

doi:10.1111/bjd.16102

Public

Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Published in British Journal of Dermatology • Nov 2, 2017

Authors:

Alexander Egeberg

Mathias Bo Ottosen

Robert Gniadecki

Abstract

BACKGROUND: Real-life data on newer biological and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originator...

Subject

Biosimilar

Plaque psoriasis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!